CERTIFICATE UNDER 37 CFR § 1.10 OF MAILING BY "EXPRESS MAIL"

JAN 1 8 2007 8

EV 847359606 US

USPS Express Mail Label Number

January 18, 2007

Date of Deposit

y certify that this correspondence is being deposited with the United States Postal Services "Express Mail Post Office to Addressee" service 37 CFR § 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, 2313-1450.

Linda H. Matsumi

PATENT

Customer No. 22,852

Attorney Docket No. 07705.0001-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	Application of:)
	Brian ZAMBROWICZ et al.) Group Art Unit: 1632
Application No.: 10/797,613) Examiner: Shin Lin CHEN
Filed:	March 9, 2004))
For:	VECTORS FOR GENE MUTAGENESIS AND GENE DISCOVERY) Confirmation No.: 3971)

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

AMENDMENT AND RESPONSE

Applicants now respond to the Office Action mailed July 19, 2006. The period for reply has been extended three months by the Petition for Three Month Extension of Time and fee payment filed concurrently herewith. Applicants respectfully request reconsideration and withdrawal of all outstanding rejections. Please enter the following amendments:

Amendments to the Specification begin at page 3.

Amendments to the Claims begin at page 8.

Remarks begin at page 14.

01/23/2007 SSITHIB1 00000097 10797613

01 FC:1253

1020.00 OP

Attorney Docket No. 07705.0001-01000

Application No.: 10/797,613

Customer No. 22,852

Attachments to this amendment include: (1) Gossler et al., "Transgenesis by means of blastocyst-derived embryonic stem cell lines," *Proc. Natl. Acad. Sci. USA* 83:9065-9069 (1986); (2) Hawkins et al. (1996) "Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents." *Cancer Res.* 56:892-898; (3) Link et al. (1996) "Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c." *Science* 273:803-805; (4) Jones et al. (2005) "Promotion of mammary cancer development by tamoxifen in a mouse model of Brca-1-mutation-related breast cancer." *Oncogene* 24(22):3554-62; and (5) Declaration of Brian Zambrowicz, Glenn A. Friedrich, and Arthur T. Sands under 37 C.F.R. § 1.132 (2 signed copies).